Latest Strategy Changes News

Beamtree Holdings has forged a strategic alliance with the NHS Confederation to launch a pioneering healthcare analytics platform across UK NHS Trusts, marking a significant step in its international expansion.

Havilah Resources reports significant progress on its copper-gold-cobalt projects Kalkaroo and Mutooroo, alongside promising regional exploration and strategic funding efforts.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Axel REE Limited announces a strategic leadership transition as it moves from exploration to development of its rare earth and gallium projects in Brazil, appointing new technical experts and seeking a new Managing Director to guide its next growth phase.

DXN Limited has completed the purchase of the Secure Data Centre Darwin property, backed by a $5 million refinancing that reduces debt and boosts cash flow by $266,000 annually.

Mineral Commodities Ltd has confirmed an extension to the completion deadline for the sale of its Skaland Graphite Project, now set for no later than June 9, 2025, with financial penalties if delayed further.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

Cavalier Resources has cleared a key technical hurdle with Raptor Capital completing due diligence on the Crawford Gold Project, paving the way for binding $11 million stream finance negotiations. The updated Pre-Feasibility Study reinforces the project's strong economic potential.

Findi Limited has reported record FY25 financial results, exceeding revenue guidance and expanding its ATM and digital financial services footprint across India. The company is advancing towards a Payments Bank license and plans an IPO of its Indian subsidiary by the end of 2026.

Findi Limited has reported record FY25 revenue and EBITDA growth, driven by key acquisitions and expanded ATM and digital payment networks across India. The company’s strengthened balance sheet and contract wins set the stage for its subsidiary’s planned 2026 IPO.

Findi Ltd reports flat revenue and a 15% rise in EBITDA but swings to a $12.5 million net loss for FY2025, driven by strategic capital raises and refinancing in its Indian subsidiary.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.